Cat. No.: HY-B0272

Rifampicin

(Synonyms: Rifampin; Rifamycin AMP)

45 Cited Publications

Avis client

Based on 45 publication(s) in Google Scholar

Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities. Rifampicin shows anti-orthopoxvirus activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.23%
CAS No.: 13292-46-1
Formule: C₄₃H₅₈N₄O₁₂
Masse moléculaire:822.94

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Rifampicin Chemical Structure

CAS No.: 13292-46-1

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (45)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities. Rifampicin shows anti-orthopoxvirus activity.

Voir tous les produits spécifiques à Isoform Antibiotic :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	>100 μg/mL Compound: RP	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 27013391]
A549	GI₅₀	>100 μg/mL Compound: Rifampicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28110868]
A549	GI₅₀	>100 μg/mL Compound: Rifampicin	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 28411559]
A549	GI₅₀	>100 μg/mL Compound: RP	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 30910461]
A549	GI₅₀	>100 μg/mL Compound: RIF	Cytotoxicity against human A549 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human A549 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
A549	GI₅₀	>121.51 mM Compound: RP	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	10.1039/C6MD00278A
B-cell	IC₅₀	96 μM Compound: Rifampin	Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs	[PMID: 19075064]
CHO	CC₅₀	512 μM Compound: RIF	Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31525660]
HCT-116	CC₅₀	>100 μg/mL Compound: Rifampicin	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 27301367]
HCT-116	GI₅₀	>100 μg/mL Compound: RIF	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 27914801]
HCT-116	GI₅₀	>100 μg/mL Compound: Rifampicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28110868]
HCT-116	GI₅₀	>100 μg/mL Compound: RIF	Cytotoxicity against human HCT116 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human HCT116 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
HCT-116	GI₅₀	>121.51 mM Compound: RP	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	10.1039/C6MD00278A
HEK293	IC₅₀	1.2 μM Compound: Rifampicin	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	1.5 μM Compound: Rifampicin	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	65 μM Compound: Rifampicin	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	0.3 μM Compound: Rifampicin	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate	[PMID: 22587986]
HEK293	IC₅₀	2.2 μM Compound: Rifampicin	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate	[PMID: 22587986]
HEK293	IC₅₀	2.3 μM Compound: Rifampicin	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate	[PMID: 22587986]
HEK293	EC₅₀	1.1 μM Compound: Rifampicin	Agonist activity at human PXR transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay Agonist activity at human PXR transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 26905831]
HEK293	CC₅₀	>100 μM Compound: Rifampicin	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay	[PMID: 30392371]
HeLa	IC₅₀	270 μg/mL Compound: rifampin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	>20 μM Compound: RIF	Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 26948407]
HeLa	IC₅₀	>20 μM Compound: RIF	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26948407]
HeLa	GI₅₀	>100 μg/mL Compound: RP	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27013391]
HeLa	CC₅₀	>100 μg/mL Compound: Rifampicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 27301367]
HeLa	GI₅₀	>100 μg/mL Compound: Rifampicin	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 28411559]
HeLa	GI₅₀	>100 μg/mL Compound: RP	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 30910461]
Hepatocyte	EC₅₀	0.98 μM Compound: Rifampicin	Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method	[PMID: 22815312]
Hepatocyte	EC₅₀	1.3 μM Compound: Rifampicin	Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method	[PMID: 22815312]
Hepatocyte	IC₅₀	>20 μM Compound: RIF	Cytotoxicity against primary human hepatocytes assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against primary human hepatocytes assessed as cell viability after 48 hrs by MTS assay	[PMID: 26948407]
HepG2	EC₅₀	3.2 μM Compound: Rifampicin	Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis	[PMID: 20966043]
HepG2	EC₅₀	3.5 μM Compound: Rifampicin	Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
HepG2	IC₅₀	22.2 μM Compound: 75	Antimalarial activity against liver stages of Plasmodium yoelii 17XNL expressing GFP infected in human HepG2 cells transfected with CD81 assessed as growth inhibition of hepatic parasite after 40 hrs by flow cytometry Antimalarial activity against liver stages of Plasmodium yoelii 17XNL expressing GFP infected in human HepG2 cells transfected with CD81 assessed as growth inhibition of hepatic parasite after 40 hrs by flow cytometry	[PMID: 22122518]
HepG2	EC₅₀	0.19 μM Compound: Rifampicin	Agonist activity at PXR expressed in human HepG2 cells after 24 hrs by p3A4-luciferase reporter gene assay Agonist activity at PXR expressed in human HepG2 cells after 24 hrs by p3A4-luciferase reporter gene assay	[PMID: 27145071]
HepG2	IC₅₀	145.33 μM Compound: Rifampicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 32249118]
HepG2	CC₅₀	175.9 μg/mL Compound: RIF	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33940463]
HepG2	IC₅₀	>500 μM Compound: RIF	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability	[PMID: 37423128]
Huh-7	IC₅₀	>20 μM Compound: RIF	Cytotoxicity against human HuH7 cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against human HuH7 cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 26948407]
Huh-7	IC₅₀	>20 μM Compound: RIF	Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26948407]
J774.A1	CC₅₀	207.03 μg/mL Compound: rifampin	Cytotoxicity against mouse J774A1 cells after 24 to 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells after 24 to 72 hrs by MTT assay	[PMID: 20934344]
J774.A1	IC₅₀	>100 μM Compound: RIF	Cytotoxicity against mouse J774A1 cells assessed as cell viability after 24 hrs by Trypan blue exclusion assay Cytotoxicity against mouse J774A1 cells assessed as cell viability after 24 hrs by Trypan blue exclusion assay	[PMID: 24611928]
J774.A1	IC₅₀	>64 μg/mL Compound: RFP	Cytotoxicity against mouse J774.A1 cells after 48 hrs by MTT assay Cytotoxicity against mouse J774.A1 cells after 48 hrs by MTT assay	[PMID: 36150342]
Macrophage	IC₅₀	>100 μM Compound: Rifampicin	Cytotoxicity against mouse bone marrow derived macrophage assessed as growth inhibition after 48 hrs by MTS assay Cytotoxicity against mouse bone marrow derived macrophage assessed as growth inhibition after 48 hrs by MTS assay	[PMID: 23454512]
MCF7	GI₅₀	>100 μg/mL Compound: RIF	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 27914801]
MCF7	GI₅₀	>100 μg/mL Compound: Rifampicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 28110868]
MCF7	GI₅₀	>100 μg/mL Compound: RIF	Cytotoxicity against human MCF7 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human MCF7 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
MCF7	GI₅₀	>121.51 mM Compound: RP	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	10.1039/C6MD00278A
MDCK-II	IC₅₀	>20 μM Compound: RIF	Cytotoxicity against MDCK2-MDR1 cells assessed as cell viability after 24 hrs by MTS assay Cytotoxicity against MDCK2-MDR1 cells assessed as cell viability after 24 hrs by MTS assay	[PMID: 26948407]
MDCK-II	IC₅₀	>20 μM Compound: RIF	Cytotoxicity against MDCK2-MDR1 cells assessed as cell viability after 48 hrs by MTS assay Cytotoxicity against MDCK2-MDR1 cells assessed as cell viability after 48 hrs by MTS assay	[PMID: 26948407]
MG-63	IC₅₀	240 μg/mL Compound: rifampin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MRC5	IC₅₀	>100 μM Compound: Rifampicin	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method	[PMID: 26213786]
Osteoblast	IC₅₀	130 μg/mL Compound: rifampin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
PANC-1	GI₅₀	>100 μg/mL Compound: RP	Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 27013391]
PANC-1	CC₅₀	>100 μg/mL Compound: Rifampicin	Cytotoxicity against human PANC1 cells by MTT assay Cytotoxicity against human PANC1 cells by MTT assay	[PMID: 27301367]
PANC-1	GI₅₀	>100 μg/mL Compound: Rifampicin	Growth inhibition of human PANC1 cells by MTT assay Growth inhibition of human PANC1 cells by MTT assay	[PMID: 28411559]
PANC-1	GI₅₀	>100 μg/mL Compound: RP	Growth inhibition of human PANC1 cells by MTT assay Growth inhibition of human PANC1 cells by MTT assay	[PMID: 30910461]
PBMC	IC₅₀	62.92 μg/mL Compound: RIF	Cytotoxicity against human PBMC assessed as reduction in cell growth after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as reduction in cell growth after 72 hrs by MTT assay	[PMID: 32977201]
RAW264.7	GI₅₀	700 μg/mL Compound: RIF	Cytotoxicity against mouse RAW264.7 cells Cytotoxicity against mouse RAW264.7 cells	[PMID: 25921267]
RAW264.7	CC₅₀	24 μM Compound: RIF	Cytotoxicity against mouse RAW264.7 cells Cytotoxicity against mouse RAW264.7 cells	[PMID: 33071055]
RAW264.7	CC₅₀	80.39 μg/mL Compound: RIF	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33940463]
RAW264.7	GI₅₀	850 μM Compound: RIF	Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay	10.1039/C3MD00251A
Sf21	IC₅₀	11.3 μM Compound: Rifampicin	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	34.7 μM Compound: Rifampicin	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
THP-1	IC₅₀	>100 μM Compound: Rifampicin	Cytotoxicity against human THP1 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method Cytotoxicity against human THP1 cells assessed as cell growth inhibition after 48 hrs by resazurin dye reduction method	[PMID: 26213786]
THP-1	IC₅₀	0.0018 μg/mL Compound: Rifampicin	Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive dormant phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive dormant phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay	[PMID: 26299346]
THP-1	IC₅₀	0.0021 μg/mL Compound: Rifampicin	Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive active phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay Anti-tubercular activity against rifampicin, isoniazid, ethambutol and pyrazinamide-sensitive active phage of Mycobacterium tuberculosis H37Ra ATCC 25177 infected in human THP1 cells by neutral red assay	[PMID: 26299346]
THP-1	GI₅₀	>100 μg/mL Compound: RP	Cytotoxicity against human THP1 cells after 48 hrs by MTT assay Cytotoxicity against human THP1 cells after 48 hrs by MTT assay	[PMID: 27013391]
THP-1	CC₅₀	>100 μg/mL Compound: Rifampicin	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 27301367]
THP-1	GI₅₀	>100 μg/mL Compound: RIF	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 27914801]
THP-1	GI₅₀	0.14 μg/mL Compound: Rifampicin	Cytotoxicity against human THP1 cells assessed as growth inhibition by MTT assay Cytotoxicity against human THP1 cells assessed as growth inhibition by MTT assay	[PMID: 28103537]
THP-1	CC₅₀	>64 μg/mL Compound: RFP	Cytotoxicity against human THP-1 cells incubated for 48 hrs by MTS/PMS assay Cytotoxicity against human THP-1 cells incubated for 48 hrs by MTS/PMS assay	[PMID: 37300914]
THP-1	GI₅₀	>100 μg/mL Compound: RIF	Cytotoxicity against human THP1 cells incubated for 1 to 11 days by MTT assay Cytotoxicity against human THP1 cells incubated for 1 to 11 days by MTT assay	10.1039/C5MD00404G
Vero	IC₅₀	147 μg/mL Compound: Rifampin	Compound was tested for its cytotoxicity on Vero cells Compound was tested for its cytotoxicity on Vero cells	[PMID: 10762047]
Vero	IC₅₀	>1000 μg/mL Compound: Rifampicin	Cytotoxicity determined in VERO cells at concentrations less than or equal to 62.5 mg/mL or 10 times the MIC against Mycobacterium tuberculosis H37Rv. Cytotoxicity determined in VERO cells at concentrations less than or equal to 62.5 mg/mL or 10 times the MIC against Mycobacterium tuberculosis H37Rv.	[PMID: 11425535]
Vero	IC₅₀	110.67 μg/mL Compound: Rifampin	In vitro cytotoxicity against VERO cell line In vitro cytotoxicity against VERO cell line	[PMID: 12139444]
Vero	IC₅₀	134.48 μM Compound: Rifampin	In vitro cytotoxicity against VERO cell line In vitro cytotoxicity against VERO cell line	[PMID: 12139444]
Vero	IC₅₀	100 μg/mL Compound: Rifampin	Inhibitory concentration required to produce cytotoxicity against VERO cells Inhibitory concentration required to produce cytotoxicity against VERO cells	[PMID: 16005211]
Vero	IC₅₀	>62.5 μg/mL Compound: Rifa	Cytotoxicity against Vero cell line Cytotoxicity against Vero cell line	[PMID: 16759086]
Vero	IC₅₀	>75.94 μM Compound: rifampicin	Cytotoxicity against Vero cells after 72 hrs by MTT assay Cytotoxicity against Vero cells after 72 hrs by MTT assay	[PMID: 17276683]
Vero	IC₅₀	>100 μg/mL Compound: rifampin	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17561405]
Vero	IC₅₀	>100 μM Compound: rifampicin	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17562368]
Vero	IC₅₀	89.3 μg/mL Compound: RMP	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 18818073]
Vero	IC₅₀	>100 μg/mL Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19058970]
Vero	IC₅₀	138.3 μM Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay	[PMID: 19119013]
Vero	IC₅₀	>75.9 μM Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19131245]
Vero	IC₅₀	127 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs by Cell titer assay Cytotoxicity against african green monkey Vero cells after 72 hrs by Cell titer assay	[PMID: 19271749]
Vero	IC₅₀	97.9 μM Compound: rifampin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 19371071]
Vero	IC₅₀	127 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 19757815]
Vero	IC₅₀	122 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 19863050]
Vero	IC₅₀	100 μg/mL Compound: rifampin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19926361]
Vero	IC₅₀	>75.94 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19942326]
Vero	IC₅₀	122 μM Compound: 1	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 20000470]
Vero	IC₅₀	122 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 20022500]
Vero	IC₅₀	>62.5 μg/mL Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 20056418]
Vero	IC₅₀	125 μM Compound: Rifampin	Cytotoxicity against african green monkey Vero cells by colorimetric assay Cytotoxicity against african green monkey Vero cells by colorimetric assay	[PMID: 20116900]
Vero	IC₅₀	>100 μg/mL Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 20233660]
Vero	IC₅₀	>74.5 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero after 72 hrs by MTT assay	[PMID: 20576327]
Vero	CC₅₀	>75.94 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 20615698]
Vero	CC₅₀	180 μM Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat	[PMID: 21146257]
Vero	IC₅₀	113 μM Compound: RMP, RFC	Cytotoxicity against african green monkey Vero cells after 72 hrs Cytotoxicity against african green monkey Vero cells after 72 hrs	[PMID: 21691438]
Vero	IC₅₀	113 μM Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiter assay Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiter assay	[PMID: 22391032]
Vero	CC₅₀	>50 μg/mL Compound: RIF	Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay	[PMID: 22691154]
Vero	IC₅₀	>100 μM Compound: Rifampin	Cytotoxicity against african green monkey Vero cells at < 10 uM after 3 days Cytotoxicity against african green monkey Vero cells at < 10 uM after 3 days	[PMID: 22850215]
Vero	CC₅₀	>500 μg/mL Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23062712]
Vero	IC₅₀	>62.5 μg/mL Compound: Rifampin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23352268]
Vero	IC₅₀	>100 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 24 hrs by MTS assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 24 hrs by MTS assay	[PMID: 23454512]
Vero	IC₅₀	58 μg/mL Compound: Rifampicin	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 23850103]
Vero	IC₅₀	132.5 μM Compound: RMP	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay	[PMID: 24079882]
Vero	IC₅₀	108 μM Compound: RMP, rifampicin	Cytotoxicity against african green monkey Vero cells by tetrazolium dye reduction assay Cytotoxicity against african green monkey Vero cells by tetrazolium dye reduction assay	[PMID: 24084159]
Vero	IC₅₀	>100 μg/mL Compound: RMP	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS-PMS assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS-PMS assay	[PMID: 24087924]
Vero	IC₅₀	142.9 μg/mL Compound: RMP	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 24224794]
Vero	IC₅₀	>182 μM Compound: Rifampin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 24314672]
Vero	IC₅₀	>62.5 μg/mL Compound: Rifampicin	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24721315]
Vero	IC₅₀	113 μM Compound: rifampicin	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by CellTiter 96 assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by CellTiter 96 assay	[PMID: 24909079]
Vero	CC₅₀	>150 μg/mL Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 26498570]
Vero	IC₅₀	>100 μM Compound: RMP	Cytotoxicity against African green monkey Vero cells by MTS assay Cytotoxicity against African green monkey Vero cells by MTS assay	[PMID: 26748697]
Vero	IC₅₀	>100 μM Compound: Rifampicin	Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 27426865]
Vero	IC₅₀	>50 μM Compound: 52	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by tetrazolium dye assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by tetrazolium dye assay	[PMID: 28094223]
Vero	IC₅₀	>256 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 28574259]
Vero	CC₅₀	500 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28646656]
Vero	CC₅₀	500 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28720502]
Vero	CC₅₀	512 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29227930]
Vero	IC₅₀	>100 μM Compound: RMP	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS/PMS assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS/PMS assay	[PMID: 29259747]
Vero	CC₅₀	7.8 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 29407980]
Vero	CC₅₀	512 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30025351]
Vero	IC₅₀	>200 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30145051]
Vero	IC₅₀	97.4 μg/mL Compound: Rifampin	Cytotoxicity against African green monkey Vero cells by CellTiter 96 aqueous nonradioactive cell proliferation assay Cytotoxicity against African green monkey Vero cells by CellTiter 96 aqueous nonradioactive cell proliferation assay	[PMID: 30295480]
Vero	CC₅₀	512 μM Compound: RIF	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 30296686]
Vero	CC₅₀	512 μg/mL Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30690301]
Vero	IC₅₀	>100 μg/mL Compound: RMP	Cytotoxicity against African green monkey Vero cells measured after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Cytotoxicity against African green monkey Vero cells measured after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 30891129]
Vero	CC₅₀	512 μM Compound: RIF	Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30992202]
Vero	CC₅₀	>128 μg/mL Compound: Rifampicin	Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay	[PMID: 31352245]
Vero	CC₅₀	>32 μg/mL Compound: Rifampicin	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31353295]
Vero	CC₅₀	128 μg/mL Compound: Rifampicin	Cytotoxicity in African green monkey Vero cells Cytotoxicity in African green monkey Vero cells	[PMID: 31358466]
Vero	IC₅₀	137.6 μg/mL Compound: Rifampicin	Cytotoxicity against African green monkey Vero cells incubated for 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells incubated for 24 hrs by MTT assay	[PMID: 31951961]
Vero	IC₅₀	>122 μM Compound: RMP	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 32031795]
Vero	IC₅₀	>64 μg/mL Compound: Rfp	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 34126456]
Vero	IC₅₀	>64 μg/mL Compound: RFP	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 36150342]
Vero	IC₅₀	>64 μg/mL Compound: RFP	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 37348296]
Vero	IC₅₀	>100 μg/mL Compound: RFP	Cytotoxicity against african green monkey Vero cells incubated for 48 hrs by CCK8 assay Cytotoxicity against african green monkey Vero cells incubated for 48 hrs by CCK8 assay	[PMID: 39166949]
Vero	IC₅₀	>158 μg/mL Compound: rifampin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 9677287]
Vero	IC₅₀	105 μM Compound: RMP, rifampin	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells	10.1007/s00044-007-9073-0
Vero	IC₅₀	>77.4 μM Compound: Rifampicin	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 72 hr	10.1007/s00044-010-9322-5
Vero	CC₅₀	>75.9 μM Compound: rifampicin	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 72 hr by MTT assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as cell viability after 72 hr by MTT assay	10.1007/s00044-011-9638-9
Vero	IC₅₀	>10 μg/mL Compound: RIP	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as inhibition of cell viability after 96 hr by MTT assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as inhibition of cell viability after 96 hr by MTT assay	10.1007/s00044-012-0074-2

In Vitro

Rifampicin (100 microg/mL) can block the functional activity of P-glycoprotein. Rifampicin is not a substract for P-glycoprotein. The mechanism of rifampicin resistance is unassociated with the functional activity of P-glycoprotein^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rifampicin (200, 400 mg/kg) can induce fatty liver at high concentration^[1]. Rifampicin (30 mg/kg, i.p.) treatment of S464P biofilms in vivo results in a slight decline, but earlier rebinds in bioluminescence from these catheters compared with the parental signal, whereas rifampicin has no affect on bioluminescence in mice infected with mutant H481Y^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 13292-46-1
Appearance Solid
Masse moléculaire 822.94
Formule C₄₃H₅₈N₄O₁₂
Color Orange to red
SMILES

OC(C(/C=N/N1CCN(C)CC1)=C(NC(/C(C)=C\C=C\[C@@H]([C@@H]([C@@H](C)[C@H]2O)O)C)=O)C(O)=C3C(O)=C4C)=C3C5=C4O[C@](C)(O/C=C/[C@@H]([C@H]([C@@]([C@@H]2C)([H])OC(C)=O)C)OC)C5=O
Synonyms

Rifampin; Rifamycin AMP
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (45)

All Bio/Physico-chemical AssayMicrobiological AssayCell Imaging/StainingFlow CytometryWB

Sort by:

Journal Impact Factor

Cell

A microbial amino-acid-conjugated bile acid, tryptophan-cholic acid, improves glucose homeostasis via the orphan receptor MRGPRE. [Abstract]

2025 Aug 21;188(17):4530-4548.e25. PMID: 40446798
Acta Pharm Sin B

Generation and applications of an expandable and mature hiPSC-derived liver organoid. [Abstract]

2025 Dec;15(12):6382-6398. PMID: 41477334
Adv Sci (Weinh)

A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics. [Abstract]

2020 Jul 21;7(17):2001374. PMID: 32995131

Rifampicin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jul 21;7(17):2001374. [Abstract]

Rapid killing kinetics of the combination (>99.9% killing in 10 min). pEt_20: 0.5× MIC (7.8 µg/mL), rifampicin: 0.5× MIC (0.50 µg/mL). Limit of detection: 50 CFU/mL.

Rifampicin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jul 21;7(17):2001374. [Abstract]

Fluorescence intensity analysis of intracellular ROS probe CellRox Green in A. baumannii BAA‐1709 (≈107 CFU/mL) after treatment with rifampicin (0.50 µg/mL), pEt_20 , and their combination over various periods of time (0-30 min).

Rifampicin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jul 21;7(17):2001374. [Abstract]

Flow cytometric analysis of intracellular ROS levels after 10 min treatment with rifampicin (0.5 µg/mL), pEt_20, or their combination.
EBioMedicine

Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin. [Abstract]

2025 May 30:117:105776. PMID: 40449326
Plant Biotechnol J

Engineering of 10-Deacetylbaccatin III-10-β-O-Acetyltransferase From Taxus Species for Efficient Acetylating Non-Natural Substrates Into Taxol in Nicotiana benthamiana. [Abstract]

2026 May;24(5):3308-3323. PMID: 41618615
Acta Pharmacol Sin

Species differences in the hepatobiliary disposition of morphine-6-glucuronide mediated by hepatic transporters in rats and humans. [Abstract]

2025 Sep 15. PMID: 40954191
Acta Pharmacol Sin

Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening. [Abstract]

2022 Jun;43(6):1605-1615. PMID: 34667293

Rifampicin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2022 Jun;43(6):1605-1615. [Abstract]

The antibacterial activity of compound B2 and H3 against M. smegmatis. The TBA-7371 and rifampin (7 d) were used as positive controls.
Phytomedicine

Potential detoxification effect of active ingredients in liquorice by upregulating efflux transporter. [Abstract]

2019 Mar 15:56:175-182. PMID: 30668338

Rifampicin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2019 Mar 15:56:175-182. [Abstract]

Representative Western blots for P-gp、BCRP、MRP2 in LS-180 treated with six active compounds in liquorice. C: control, P-1: Rifampicin, P-2: Bosentan, S-1: Liquiritin, S-2: Liquiritigenin, S-3: Isoliquiritin, S-4: Isoliquiritigenin, S-5: Glycyrrhetinic acid, S-6: Licochalcone A.
Biomed Pharmacother

Integrated pharmacokinetic properties and tissue distribution of Corydalis saxicola Bunting total alkaloids in HFHCD-induced mice: Implications for pharmacokinetic variability in MASH treatment. [Abstract]

2025 Oct 21:192:118665. PMID: 41124864
Biomed Pharmacother

The enhancement effect of small molecule Lyb24 reveals AzoR as a novel target of polymyxin B. [Abstract]

2023 Dec 31:169:115856. PMID: 37949698
J Med Chem

Design, Synthesis, and Biological Evaluation of Mono- and Diamino-Substituted Squaramide Derivatives as Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthase. [Abstract]

2025 Dec 11;68(23):25274-25289. PMID: 41277442
J Med Chem

Discovery of N-(1-(6-Oxo-1,6-dihydropyrimidine)-pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium tuberculosis. [Abstract]

2024 Feb 8;67(3):1914-1931. PMID: 38232131
J Agric Food Chem

Genistein Ameliorates Rifampicin-Undermined Hepatic Cholesterol Efflux via the CH25H-LXRα-ABCA Pathway. [Abstract]

2025 Dec 29. PMID: 41459645
Commun Biol

The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses. [Abstract]

2025 Oct 6;8(1):1425. PMID: 41053365
PLoS Pathog

Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]

2026 Jan 26;22(1):e1013903. PMID: 41587213
Int Immunopharmacol

Synergistic and mechanistic effects of neogambogic acid in enhancing almonertinib sensitivity in non-small cell lung cancer. [Abstract]

2025 May 23:159:114878. PMID: 40412130
Int J Cancer

Darolutamide does not interfere with OATP-mediated uptake of docetaxel. [Abstract]

2024 Jul 15;155(2):314-323. PMID: 38491867
Microbiologyopen

Antibacterial and Antibiofilm Activity of Closantel Against Staphylococcus epidermidis. [Abstract]

2025 Oct;14(5):e70062. PMID: 40926309
RSC Adv

Identification of key transporters mediating uptake of aconitum alkaloids into the liver and kidneys and the potential mechanism of detoxification by active ingredients of liquorice. [Abstract]

2019 May 23;9(28):16136-16146. PMID: 35521419
Antimicrob Agents Chemother

Incorporation of macrophage immune stresses into an intracellular assay of drug tolerance in Mycobacterium tuberculosis. [Abstract]

2025 Sep 11:e0079525. PMID: 40934365
mLife

Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]

2025 Apr 15;4(2):155-168. PMID: 40313980
Mol Pharm

Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model. [Abstract]

2024 May 6;21(5):2284-2297. PMID: 38529622
ACS Omega

Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]

2025 Oct 29;10(44):52562-52575. PMID: 41244417
ACS Omega

Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. [Abstract]

2022 Mar 3;7(10):9004-9014. PMID: 35309438
iScience

Loratadine inhibits Staphylococcus aureus virulence and biofilm formation. [Abstract]

2022 Jan 5;25(2):103731. PMID: 35098100
Drug Metab Dispos

Species difference in the excretion routes of Ciprofol (HSK3486) in rats and humans: Contribution of hepatic transporters and renal UDP-glucuronosyltransferase enzymes. [Abstract]

2025 Jun;53(6):100083. PMID: 40456195
ACS Infect Dis

Loratadine Derivative Lo-7: A Weapon against Drug-Resistant Enterococcus and Streptococcal Infections. [Abstract]

2024 Aug 9;10(8):2961-2977. PMID: 39066703
Microbiol Spectr

Repurposing 9-Aminoacridine as an Adjuvant Enhances the Antimicrobial Effects of Rifampin against Multidrug-Resistant Klebsiella pneumoniae. [Abstract]

2023 Jun 15;11(3):e0447422. PMID: 37036368
Microbiol Spectr

The Mechanism of Action of Ginkgolic Acid (15:1) against Gram-Positive Bacteria Involves Cross Talk with Iron Homeostasis. [Abstract]

2022 Feb 23;10(1):e0099121. PMID: 35019708
ACS Chem Biol

Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents. [Abstract]

2022 Jan 21;17(1):39-53. PMID: 34908399
Cancer Res Commun

Drug-drug interaction liabilities with BTK inhibitor TL-895. [Abstract]

2025 Aug 22. PMID: 40844833
Neurotox Res

Duloxetine-Induced Neural Cell Death and Promoted Neurite Outgrowth in N2a Cells. [Abstract]

2020 Dec;38(4):859-870. PMID: 32415528
mSphere

RND Pump-Mediated Efflux of Amotosalen, a Compound Used in Pathogen Inactivation Technology to Enhance Safety of Blood Transfusion Products, May Compromise Its Gram-Negative Anti-Bacterial Activity. [Abstract]

2023 Apr 20;8(2):e0067322. PMID: 36853056
J Biochem Mol Toxicol

Network Toxicology and Molecular Docking Analysis of Antituberculosis Drug-Induced Hepatotoxicity. [Abstract]

2025 Nov;39(11):e70602. PMID: 41215592
Onco Targets Ther

MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. [Abstract]

2018 Sep 17:11:5885-5894. PMID: 30271172

Rifampicin purchased from MedChemExpress. Usage Cited in: Onco Targets Ther. 2018 Sep 17:11:5885-5894. [Abstract]

MHCC97-H cells are treated with the indicated concentrations of Rifampicin for 48 hours. Then, cells are harvested for Western blot analysis.
Future Microbiol

Synergistic drug strategy against mastitis-associated MRSA strains. [Abstract]

2025 Oct 13:1-10. PMID: 41082411
Biochem Biophys Res Commun

High-throughput screening unveils AMG 837 and RORγt 13 as the potent Brucella inhibitor by targeting BacA. [Abstract]

2025 Apr 9:757:151624. PMID: 40090117

Rifampicin purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 Apr 9:757:151624. [Abstract]

Ability of different concentrations compounds or drugs (GM, Gentamicin, Sterile; AMG 837; RORγt 13; RIF; 4, 16 μg/mL) to clear B. melitensis TZ in RAW264.7 cells at 24 h. Cells appear blue; B. melitensis TZ appear green.
Biopharm Drug Dispos

Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells. [Abstract]

2022 Dec;43(6):265-271. PMID: 36195987
Xenobiotica

Effects of liquorice on pharmacokinetics of aconitine in rats. [Abstract]

2019 Dec;49(12):1485-1493. PMID: 30741588
SSRN

2025 May 7.
bioRxiv

2024 Nov 06.
Res Sq

Proapoptotic Bcl-2 inhibitor as host directed therapy for pulmonary tuberculosis. [Abstract]

2024 Sep 2:rs.3.rs-4926508. PMID: 39281866
Research Square Print

2022.
University of Manitoba

2022 Jan.
Patent

US20200101105A1.

Solvant et solubilité

In Vitro:

DMSO : 70 mg/mL (85.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2152 mL

6.0758 mL

12.1516 mL

5 mM

0.2430 mL

1.2152 mL

2.4303 mL

10 mM

0.1215 mL

0.6076 mL

1.2152 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (3.04 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Animal Administration^[2]

Briefly, 1 cm Teflon catheter (14-gauge) carrying 104 cfu S. aureus, either the parental strain Xen 29 or the RifR mutants S464P or H481Y, are implanted subcutaneously in groups of nine mice per strain. One catheter segment is inserted on each side of each animal. Six days after the implantation of the catheters, five mice from each group are treated with rifampicin at 30 mg/kg intraperitoneally in 0.1 mL saline, twice daily for four consecutive days. The remaining four mice in each group are left untreated as controls. At various time points during the infection, the mice are anaesthetized using a constant flow of 1.5% isoflurane from the IVIS^® manifold, and imaged using an IVIS^® Image System 100 Series. The bioluminescent signals (photons/s) emitted from the mice are analysed using LivingImage^® software and plotted over the course of infection. The mice are sacrificed 20 days after infection (11 days after final rifampicin treatment). The catheters are surgically removed and the bacteria are detached by sonication for determination of bacterial burdens on the catheters.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7. [Content Brief]

[2]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2. [Content Brief]

[3]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61. [Content Brief]

[4]. Hamzehei M, et al. Inhibition of influenza A virus replication by rifampicin and selenocystamine. J Med Virol. 1980;6(2):169-74. [Content Brief]

[5]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2152 mL	6.0758 mL	12.1516 mL	30.3789 mL
	5 mM	0.2430 mL	1.2152 mL	2.4303 mL	6.0758 mL
	10 mM	0.1215 mL	0.6076 mL	1.2152 mL	3.0379 mL
	15 mM	0.0810 mL	0.4051 mL	0.8101 mL	2.0253 mL
	20 mM	0.0608 mL	0.3038 mL	0.6076 mL	1.5189 mL
	25 mM	0.0486 mL	0.2430 mL	0.4861 mL	1.2152 mL
	30 mM	0.0405 mL	0.2025 mL	0.4051 mL	1.0126 mL
	40 mM	0.0304 mL	0.1519 mL	0.3038 mL	0.7595 mL
	50 mM	0.0243 mL	0.1215 mL	0.2430 mL	0.6076 mL
	60 mM	0.0203 mL	0.1013 mL	0.2025 mL	0.5063 mL
	80 mM	0.0152 mL	0.0759 mL	0.1519 mL	0.3797 mL

Keywords

Rifampicin

45 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Rifampicin

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Macrocyclic Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Orthopoxvirus Compound Library

Anti-Aging Natural Product Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Rifampicin

Voir tous les produits spécifiques à Isoform Antibiotic

Activité biologique

Chemical Information

Publications (45)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Rifampicin Related Classifications

Cat. No.: HY-B0272